Meriofert Set

Follicle‑Stimulating Hormone and Luteinising Hormone, the active ingredients in Meriofert Set, are gonadotropins presented as an injectable solution for subcutaneous use. They are employed to induce ovulation in women with anovulation or oligo‑ovulation and to support controlled ovarian stimulation during assisted reproductive technology cycles and to aid luteal phase support in fertility treatment protocols.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products.

Meriofert Set, a gonadotropin used in reproductive endocrinology, is indicated for the following clinical situations:

- Induction of ovulation: facilitates follicular development and ovulation in women with anovulation or oligo‑ovulation. - Controlled ovarian stimulation: enhances multiple follicle growth for assisted reproductive technology procedures. - Luteal phase support: supports corpus luteum function during fertility treatment protocols. - Polycystic ovary syndrome (PCOS) treatment: promotes follicular maturation to achieve regular ovulation in PCOS patients. - In vitro fertilization (IVF) cycles: increases oocyte yield to improve embryo availability for IVF.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Mild ovarian hyperstimulation syndrome: abdominal discomfort, bloating, and mild weight gain. - Headache. - Nausea. - Fatigue.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, thrombosis, or renal impairment. - Allergic reaction: rash, urticaria, or anaphylaxis. - Ovarian torsion: sudden pelvic pain requiring emergency intervention.

Meriofert Set should be used with careful clinical monitoring: - Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Monitor ovarian response: use ultrasound and estradiol levels to adjust dosing. - Risk of OHSS: assess risk factors and limit stimulation in high‑risk patients. - Allergy history: avoid if known hypersensitivity to gonadotropins. - Concomitant medications: review for drugs affecting ovarian response. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with other agents affecting ovarian function.

Major Interactions (Avoid): - Human chorionic gonadotropin (hCG): may exacerbate ovarian hyperstimulation; avoid concurrent use. - Estrogen‑containing oral contraceptives: can suppress endogenous gonadotropin response; discontinue before treatment. - GnRH agonists used for down‑regulation: timing must be coordinated; avoid overlapping.

Moderate Interactions (Monitor Closely): - Clomiphene citrate: may alter follicular response; monitor estradiol levels. - Letrozole: may affect ovarian stimulation; adjust dose as needed. - Thyroid hormone replacement: monitor thyroid function as gonadotropins can influence hormone metabolism.